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We have generated mice with a floxed fak allele under
the control of keratin-14-driven Cre fused to a modified
estrogen receptor (CreERT2). 4-Hydroxy-tamoxifen treat-
ment induced fak deletion in the epidermis, and sup-
pressed chemically induced skin tumor formation. Loss
of fak induced once benign tumors had formed inhibited
malignant progression. Although fak deletion was asso-
ciated with reduced migration of keratinocytes in vitro,
we found no effect on wound re-epithelialization in vivo.
However, increased keratinocyte cell death was observed
after fak deletion in vitro and in vivo. Our work provides
the first experimental proof implicating FAK in tumori-
genesis, and this is associated with enhanced apoptosis.
Supplemental material is available at http://www.genesdev.org.
Received July 1, 2004; revised version accepted October 14,
2004.
Cellular focal adhesions are complex structures consist-
ing of many interacting proteins that provide both physi-
cal adhesion to extracellular matrix, usually via trans-
membrane integrin receptors, and that also transmit
survival and/or growth signals into the cell interior. De-
regulation of these adhesions may permit cancer cells to
migrate and invade into surrounding tissue during the
development of malignant disease, or to survive and
grow under normally inappropriate conditions. One ma-
jor component of integrin adhesions is focal adhesion
kinase (FAK), a nonreceptor tyrosine kinase that is piv-
otal in many signaling pathways (Ilic et al. 1997). FAK
regulates integrin-mediated adhesion and cell migra-
tion, and contributes to proliferation and cell survival
(Schaller 2001; Hauck et al. 2002). Despite numerous
reports that FAK expression correlates with the develop-
ment of cancer (Owens et al. 1995, 1996; Agochiya et al.
1999; Jones et al. 2000; McLean et al. 2003), there is no
direct evidence whether, and if so how, FAK contributes
to cancer development.
Using fak heterozygous (+/−) mice, we previously dem-
onstrated that reduced FAK expression had a negative
impact on chemically induced papilloma formation
(McLean et al. 2001). However, these benign tumors
from fak+/− mice elevated expression of FAK to a level
that was indistinguishable from papillomas from wild-
type fak+/+ mice, preventing us from addressing the key
question of whether FAK expression is causally involved
in malignant progression. Here, we address whether FAK
plays a causal role in development of the malignant phe-
notype in vivo, by generating mice in which we had both
spatial and temporal control over fak deletion. Specifi-
cally, we used gene targeting in embryonic stem (ES)
cells to generate mice that are homozygous for a floxed
fak allele, and that also express a 4-hydroxy-tamoxifen
(4-OHT)-regulated Cre recombinase (Cre-ERT2) expressed
under control of the keratin-14 promoter (K14CreERT2/
FAKflox/flox). We could delete fak from the epidermis of
these mice upon addition of 4-OHT, but more impor-
tantly from benign papilloma tumors once these had de-
veloped. Our results provide the first evidence that FAK
modulates the efficiency of benign tumor formation and
plays a crucial role in malignant conversion.
Results and Discussion
To investigate the role of FAK during the formation and
development of skin tumors, we used Cre/loxP technol-
ogy to target the introduction of conditional mutations
into the fak gene in mice. As the fak coding exons are
spread over >225 kb, it was not practical to flox the en-
tire fak gene; instead, loxP sites were introduced into the
fak gene at positions flanking the exon encoding part of
the kinase domain, that is, FAK amino acids 413–444.
(The gene-targeting strategy and generation of FAK
floxed mice are described in detail in the Supplemental
Material.) The targeting vector was designed so that Cre-
mediated recombination also introduced a frameshift
mutation in the adjacent exon, precluding production of
a functional FAK protein. Screening of Cre-expressing ES
cells by immunoblotting confirmed that no FAK protein
was detectable (Fig. 1A). Using N-terminal antibodies to
FAK, no truncated products were visualized (data not
shown). To obtain epidermal-specific fak excision, we
crossed homozygous FAKflox/flox mice with mice ex-
pressing a modified estrogen receptor–Cre fusion protein
(CreERT2) (Indra et al. 1999), under the control of the
keratin-14 (K14) promoter. This directs 4-OHT-induced
excision of floxed fak to epidermal keratinocytes of
mouse skin (Indra et al. 1999; Li et al. 2000). The result-
ing K14CreERT2/FAKflox/flox mice were viable and dis-
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played skin-specific suppression of FAK expression fol-
lowing administration of 4-OHT, while other tissues,
such as kidney and spleen, remained unaffected (Fig. 1B).
Although some FAK was also detected in immunoblots
of epidermal extracts from 4-OHT-treated animals (Fig.
1B, lane 6), this is most likely due to FAK expression in
the underlying dermis that contaminates the epidermal
preparations, or to the presence of a small number of
keratinocytes that had not undergone FAK deletion due
to loss of K14 expression through differentiation (Stoler
et al. 1988). Immunohistochemistry revealed reduced
FAK expression in both the epidermis and hair follicles
of K14CreERT2/FAKflox/flox mice, when compared with
underlying dermis (Fig. 1C). This temporally controlled
deletion of fak allowed separation of effects on benign
tumor formation from those on malignant conversion.
Skin tumors were induced in 4-OHT-treated and un-
treated K14CreERT2/FAKflox/flox mice by a two-stage
chemical carcinogenesis protocol (Quintanilla et al.
1986; Kemp et al. 1993; Yuspa et al. 1995), as well as in
K14CreERT2 and 4-OHT-treated FAKflox/flox mice to rule
out possible effects of Cre expression or 4-OHT treat-
ment, respectively. Treatment with the carcinogen 7,12-
dimethylbenzanthracene (DMBA) gives rise to activating
mutation of the c-Ha-Ras gene (Quintanilla et al. 1986;
Pelling et al. 1987), and subsequent treatment for 20 wk
with the tumor promoter 12-O-tetradecanoylphorbol-13-
acetate (TPA) leads to formation of benign papillomas, a
proportion of which progress to form invasive squamous
cell carcinomas (SCC) (Burns et al. 1978). We observed a
marked difference in papilloma formation between
4-OHT-treated and untreated K14CreERT2/FAKflox/flox
mice. Only 50% of 4-OHT-treated mice formed papillo-
mas after 12 wk, as compared to 100% of untreated mice
(Fig. 1D). More significantly, there was also a substantial
reduction in the average number of papillomas formed
per 4-OHT-treated K14CreERT2/FAKflox/flox mouse at 22
wk when compared to the untreated control group (Fig.
1E). Additionally, no difference in benign
tumor acquisition was observed in either
the K14CreERT2 or the 4-OHT-treated
FAKflox/flox mice ruling out any possible ef-
fects of Cre expression or 4-OHT treat-
ment, respectively (data not shown). This
indicates that FAK plays a modulatory role
in chemically induced, Ras-dependent pap-
illoma formation, with half of the 4-OHT-
treated K14CreERT2/FAKflox/flox mice being
resistant to DMBA/TPA-induced benign
tumor formation. We have reported pre-
viously that keratinocytes derived from
fak+/− heterozygous mice display impaired
signaling to Ras effector pathways (McLean
et al. 2001), such as ERK/MAP kinase.
Taken with our current findings, the data
indicate that FAK is necessary not only for
the biochemical effects of Ras in cells in
culture, but also for optimal tumor initiat-
ing/promoting biological effects of onco-
genic Ras in vivo.
Experiments using immortalized fak−/−
mouse embryo fibroblasts have implicated
FAK in migration and invasion (Ilic et al.
1995), while FAK expression in tumors cor-
relates with invasive potential (Owens et
al. 1995). However, owing to the embryonic
lethality of constitutive fak deletion (Ilic et
al. 1995), no experiments have been done to
test whether FAK has a causal role in the
development of malignancy per se. We
therefore deleted fak directly from pre-
formed benign papillomas and examined
subsequent progression to invasive SCC tu-
mors. K14CreERT2/FAKflox/flox mice were
subjected to DMBA and TPA, and subse-
quently treated with 4-OHT after the ma-
jority of papillomas had formed (at 15 wk as
indicated in Fig. 2A). Immunohistochemis-
try confirmed fak gene excision after
4-OHT treatment, as judged by loss of spe-
cific FAK staining in hyperproliferative
epidermal regions of papilloma sections
(Fig. 2B, right panel). As judged by visual
identification and subsequent histological
confirmation of SCC, 4.1% of papillomas
Figure 1. Deletion of FAK from mouse skin blocks papilloma formation. (A) fak ex-
cision in ES cells following introduction of Cre recombinase. Cre was introduced by
electroporation of a pMC1-Cre plasmid, and protein extracts were harvested and sub-
jected to Western blotting with an FAK mAb. (Lanes 1–3) No Cre recombinase. (Lanes
4–6) Cre recombinase. (B) Proteins were harvested from spleen, kidney, and skin of
K14CreERT2/FAKflox/flox mice either treated with 4-OHT or with vehicle alone. Extracts
were blotted onto nitrocellulose and probed with an anti-FAK mAB (top panel) or an
anti-tubulin mAB (lower panel). (C) Immunohistochemical staining of paraffin-embed-
ded skin sections from K14CreERT2/FAKflox/flox mice treated with either 4-OHT (right
panel) or vehicle alone (left panel). (E) Epidermis; (HF) hair follicles. Deletion of fak in
epidermal keratinocytes in vivo inhibits papilloma formation during chemical carci-
nogenesis. Mice were either treated with 4-OHT () or vehicle alone (▫) and subjected
to DMBA and TPA treatment as described. Graphs indicate percent of mice acquiring
papillomas over time (D) and average numbers of papillomas recorded per mouse over
treatment time (E). Graphs represent K14CreERT2/FAKflox/flox mice.
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underwent conversion to carcinoma in untreated mice,
whereas malignant conversion of papillomas in 4-OHT-
treated K14CreERT2/FAKflox/flox mice was reduced to
0.6% (Fig. 2C). An observed conversion frequency of
3.9% in 4-OHT-treated FAKflox/flox mice excluded the
possibility of this observation being linked to adminis-
tration of 4-OHT (Fig. 2C). The 0.6% conversion fre-
quency represented two SCCs that developed in 4-OHT-
treated K14CreERT2/FAKflox/flox mice, and subsequent
immunoblotting of lysates prepared from these tumors
demonstrated retention of FAK expression at levels in
the same range as SCCs developed from untreated
K14CreERT2/FAKflox/flox mice (Fig. 2D, lanes 7,8). There-
fore, these two SCCs had arisen from papillomas in
which the fak gene had not been excised by 4-OHT treat-
ment. Crucially, FAK-deficient SCCs never arose during
our experiments, implying that loss of FAK expression
from the hyperproliferative epidermal region of papillo-
mas is incompatible with malignant progression.
Deriving keratinocytes from K14CreERT2/FAKflox/flox
mice allowed us to examine the effects of fak deletion in
the normal epithelial cells that are the targets
for tumorigenesis in the DMBA/TPA skin car-
cinogenesis model. This provides important
advantages over the commonly used fak−/−
cells (Ilic et al. 1995), not only because the
latter are mesenchymal but also because they
are deficient in p53 that might influence their
behavior (Ilic et al. 1995). Peripheral FAK
staining was visible in untreated keratino-
cytes, presumably at integrin adhesion sites
that represent keratinocyte focal adhesions,
whereas 4-OHT treatment caused loss of pe-
ripheral FAK staining in the majority of cells
(Fig. 3A). The small number of cells that con-
tinue to express FAK may be due to suppres-
sion of K14 expression that may occur as ke-
ratinocytes differentiate (Fig. 3A, right panel,
arrow; Stoler et al. 1988). We first carried out
wound repair migration assays, and found that
4-OHT-treated K14CreERT2/FAKflox/flox kera-
tinocytes were unable to repopulate the de-
nuded areas of wounded monolayers when
compared to control cultures (Fig. 3B). To ad-
dress whether this could be explained by de-
fective cell migration, we tracked individual
cells using time-lapse microscopy and found
that fak−/− keratinocytes displayed reduced
migration rates (by ∼50%), but they were still
visibly motile (Fig. 3C). However, we noticed
that there were fewer cells present even in the
confluent regions at the wound edges after 48
h (Fig. 3B, arrows), suggesting that failure to
repair the wound in vitro may be associated
with detachment and/or cell death. We col-
lected adherent and detached cells following
treatment with 4-OHT and determined the
proportion of cells with sub-2n DNA content
by FACS analysis. We found that loss of FAK
was associated with loss of normal cell cycle
profiles and a substantial amount of cell death
when compared with untreated primary kera-
tinocytes (Fig. 3D,E).
Our data thus provide the first direct experi-
mental evidence that FAK causally contrib-
utes to the development of malignancy in
vivo, specifically during the benign papilloma to SCC
transition. Furthermore, this is associated with a re-
quirement for FAK to maintain a normal rate of cell mi-
gration, and survival signaling in keratinocytes in vitro.
To determine which, if either, of these effects is likely to
be responsible for the observed suppression of tumori-
genesis upon FAK deletion, we carried out punch biopsy
wound repair assays and analyzed caspase-3 activation
in 4-OHT-treated K14CreERT2/FAKflox/flox skin to moni-
tor in vivo migration and apoptosis, respectively.
K14CreERT2/FAKflox/flox mice (either treated or un-
treated with 4-OHT) were wounded with 3-mm punch
biopsies (Fig. 4A, day 0, upper panels), and subsequent
wound closure was monitored. No visible difference in
in vivo wound repair was observed—as judged at 7 d after
wounding—when re-epithelialization was essentially
complete in both cases (Fig. 4A, day 7, lower panels).
Earlier time points at days 1 and 3 did not indicate any
lag in re-epithelialization of the wounded skin (data not
shown). In contrast, we observed a difference in staining
of activated caspase-3 both in the skin and in papillomas
Figure 2. Deletion of fak from papillomas blocks malignant progression to SCC. (A)
Mice either K14CreERT2/FAKflox/flox (left panel) or FAKflox/flox (right panel) were
treated with vehicle alone or with 4-OHT (+4-OHT) at 15 wk after the majority of
papillomas had formed. (B) Immunohistochemical anti-FAK staining of paraffin-
embedded sections of papillomas from K14CreERT2/FAKflox/flox mice treated with
vehicle alone (left panel) and with 4-OHT (right panel). (C) Papilloma to carcinoma
conversion frequency of 4-OHT-treated and untreated K14CreERT2/FAKflox/flox mice
(1 and 2) and 4-OHT-treated FAKflox/flox mice (3). Conversion frequency is deter-
mined by calculating the number of carcinomas recorded per total number of pap-
illomas for each study group. (D) Anti-FAK immunoblot of proteins extracted from
SCCs derived from untreated (lanes 1–6) or 4-OHT-treated (lanes 7,8) K14CreERT2/
FAKflox/flox mice.
McLean et al.
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from treated, but not untreated, mice (Fig. 4B). Activated
caspase-3 is accepted as a key marker of apoptotic cells
and is now widely considered to be a more reliable indi-
cator of apoptosis in tissue sections than TUNEL stain-
ing (Marshman et al. 2001; Duan et al. 2003). In partic-
ular, we observed the strongest staining in cells of the
hair follicles of 4-OHT-treated mice, where the majority
of target cells for DMBA-induced tumorigenesis are
thought to reside (Fig. 4B, middle panels; Argyris 1980).
Moreover, FAK deletion from preformed benign papillo-
mas caused stronger staining of active caspase-3 (Fig. 4B,
lower panels). Thus, it is FAK’s role in promoting cell
survival that is tightly linked to tumor formation and
progression in this mouse.
This, together with the increased expression of FAK
during acquisition of malignancy (Owens et al. 1995;
McLean et al. 2003), is in keeping with recent observa-
tions that FAK can promote invasion in vitro by regulat-
ing production of matrix metalloproteinases (Shibata et
al. 1998; Hauck et al. 2002). We have now causally im-
plicated FAK as a determinant of malignant behavior in
vivo, identifying FAK as an excellent candidate for fur-
ther study as a potential target to suppress spread of the
disease.
Materials and methods
Animals and gene targeting
Design, construction, and generation of mice containing targeted loxP
sites in the FAK gene are described in detail in the Supplemental Mate-
rial. Transgenic mice expressing the modified Cre recombinase–estrogen
receptor fusion under control of the keratin-14 promoter (K14CreERT2),
which targets Cre expression to epidermal keratinocytes, have been
described (Li et al. 2000). To facilitate cell-type-specific FAK ablation,
FAKflox/flox mice were then mated to K14CreERT2 transgenic mice. The
resulting offspring carrying K14CreERT2 that were either homozygous
for the floxed FAK gene (K14CreERT2/FAKflox/flox), carried K14CreERT2
and two copies of the wild-type FAK allele (K14CreERT2/FAK+/+) or the
Figure 3. Deletion of FAK from keratinocytes causes reduced mi-
gration and increased cell death. (A) Confocal images show anti-FAK
staining of peripheral structures in untreated (−4-OHT) or treated
(+4-OHT) keratinocytes derived from K14CreERT2/FAKflox/flox mice.
Arrows indicate FAK staining in a minority of treated keratinocytes.
Images were taken following 48 h of 4-OHT treatment. (B) Phase-
contrast images show in vitro wound-repair assays of untreated (−4-
OHT) or treated (+4-OHT) keratinocytes derived from K14CreERT2/
FAKflox/flox mice at 0 h and 48 h after the wound was made in the
monolayer. Arrows indicate areas of the monolayer at the edges of
the wound after 48 h. (C) Migration rates of keratinocytes derived
from FAKflox/flox mice (1) and K14CreERT2/FAKflox/flox mice (2),
treated with 4-OHT for 48 h, were determined by time-lapse cell
tracking and migration rate software analysis expressed as average
speed in microns per second. (D,E) Cell death of untreated (−4-OHT)
or treated (+4-OHT) keratinocytes derived from K14CreERT2/
FAKflox/flox mice was judged by the percentage of cells with sub-2n
DNA content by FACS analysis; 24 h and 48 h refers to the time of
sample collection after wounding.
Figure 4. (A) Sections of wounded skin from 4-OHT-treated (+4-
OHT) or untreated (−4-OHT) K14CreERT2/FAKflox/flox mice were
stained with H&E to examine re-epithelialization at day 0 (upper
panels) and day 7 (lower panels) post-injury. Arrows indicate the
leading edges of migrating epidermis. (B) Immunohistochemical
anti-activated caspase-3 staining of sections of either 4-OHT-treated
(+4-OHT) or untreated (−4-OHT) skin (upper and middle panels) or
papillomas (lower panels) from K14CreERT2/FAKflox/flox mice. Im-
ages taken at either low (upper panels) or high (middle and lower
panels) magnification. (HF) Hair follicles.
Focal adhesion kinase and malignant progression
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FAK floxed allele alone (FAKflox/flox), were identified by PCR analysis and
used for subsequent experiments. All animals used were crossed onto and
maintained on an FVB genetic background.
PCR genotyping
Mice that were homozygous for the floxed fak gene were routinely iden-
tified by PCR analysis. Tail DNA was prepared by standard protocols and
subjected to PCR analysis using the following primers: FAK30, 5-
AGAAAGCTATGGAATAGATGAAG-3 and FAK54, 5-GTCTGGTGT
TCTGAATAAGGTTGG-3; and the following FAK-specific amplifica-
tion protocol: 95°C/30 sec (1 cycle); 94°C/10 sec + 57°C/30 sec + 68°C/3
min (10 cycles); 94°C/10 sec + 57°C/30 sec + 68°C/3 min [+20 sec/cycle]
(20 cycles); 68°C/7 min (1 cycle). Following amplification, PCR DNA
products were digested overnight with HindIII and analyzed by agarose
gel electrophoresis. Mice that were homozygous for the floxed fak mu-
tation (FAKflox/flox) exhibited a single major band of 1.9 kb, mice that
were heterozygous for floxed FAK (FAKwt/flox) contained two major bands
at 1.9 and 1.4 kb, and wild-type (wt) mice (FAKwt/wt) contained a single
band at 1.4 kb (see Supplemental Material). Mice that additionally con-
tained the K14CreErT2 transgene were again identified by PCR analysis
using the following primers: 5-ATTTGCCTGCATTACCGGTC-3 and
5-ATCAACGTTTTCTTTTCGG-3, and standard amplification proto-
cols. Cre-positive mice exhibited a single PCR product of 350 bp.
Preparation and administration of 4-OHT
Preparation and administration of 4-OHT was as described (Indra et al.
1999) except that a reduced dose of 200 µg in 100 µL of sunflower oil was
administered. 4-OHT was administered to 8-wk-old female FVB mice as
described (Indra et al. 1999), with animals being left for 8–10 d before the
initiation of any further experimental procedures. 4-OHT for in vitro
experiments was dissolved in ethanol, stored at −20°C, and diluted before
use to a final working concentration of 10 nM.
Chemical carcinogenesis
Chemical carcinogenesis using DMBA and TPA was performed on indi-
vidual study groups of 20 female 8-wk-old animals as previously de-
scribed (McLean et al. 2001). The number of benign and malignant tu-
mors was recorded weekly for 45 wk after DMBA treatment. Benign
tumor numbers did not increase after 24 wk. Upon collection, tumor
tissue was either flash frozen in liquid nitrogen or fixed overnight in
phosphate-buffered formalin prior to paraffin embedding and histological
examination. Tumors were scored as either papillomas or carcinomas by
morphological appearance on collection, followed by histological confir-
mation after H&E staining of paraffin sections. All experiments were
carried out in accordance with the United Kingdom Animal Scientific
Procedures Act (1986).
Protein analysis
Protein extracts from tissue culture cells or frozen tissue samples were
prepared and blotted onto nitrocellulose as previously described (McLean
et al. 2001). Membranes were probed with either FAK mAb at 0.5 µg/mL
(clone 77; Transduction Laboratories), or anti-tubulin mAb (Calbio-
chem). Detection was by incubation with horseradish peroxidase-conju-
gated secondary antibody (New England Biolabs), and visualization was
by enhanced chemiluminescence (Amersham Pharmacia Biotech) ac-
cording to the manufacturer’s instructions.
Immunohistochemistry
Rabbit polyclonal antibodies against either FAK (Sigma) or activated
caspase-3 (Cell Signalling) were used to stain Formalin Fixed Paraffin
Embedded (FFPE) tissue using a two-step immunohistochemical tech-
nique. Two-micron-thick FFPE tissue sections mounted onto Superfrost
slides (Menzel-Glazer) were dewaxed in HistoClear solution (National
Diagnostics) followed by stepped rehydration via a series of graded alco-
hols to water. A negative control was compared in parallel to the inves-
tigated sections by omitting the primary antibody step. Antibody
was diluted in 0.1 g of bovine serum albumin (BDH), 0.01 g of Sodium
Azide (BDH) in 0.01 M Tris-buffered saline (pH 7.5) and incubated for
2 h at room temperature, followed by visualization with a Cytomation
EnVision kit (DAKO) (as per manufacturers’ instructions). All staining
was performed using a Sequenza (Thermoshandon) semiautomated stain-
ing facility. Resulting sections were analyzed and images were captured
digitally using a Zeiss Axioskop 50 microscope and Axiovision software
version 3.1.
Generation of murine keratinocytes
Primary murine keratinocytes were prepared and propagated from dorsal
skin sections of 1- to 2-d-old mice as previously described (McLean et al.
2001). Harvested cells were then plated onto collagen-I precoated tissue
culture dishes (Becton Dickinson), and maintained in a humid 37°C/3%
CO2 incubator in keratinocyte growth medium (KGM; Clonetics). For
experiments involving fak deletion, keratinocytes were pretreated with
either 4-OHT (10 nM) in ethanol or vehicle alone, for 48 h with one
change of medium and drug at 24 h. This concentration of tamoxifen was
identified by titration experiments to be a dose that induced loss of FAK
without adverse effects on control cultures.
Wound healing assay
For in vitro wound healing experiments, K14CreErT2/FAKflox/flox kera-
tinocytes were grown to confluence in 60-mm collagen-I-coated tissue
culture dishes (Becton Dickinson) in KGM. Monolayers were wounded
using a micropipette tip, and the cells were rinsed with KGM before
visualization using a phase-contrast microscope. Cells were treated with
either 10 nM 4-OHT or vehicle alone for 48 h before wounding. Wound
closure was recorded at 0 and 48 h after 4-OHT removal.
For in vivo wound healing experiments, K14CreERT2/FAKflox/flox mice
were injected intraperitoneally with 4-OHT as described. Mice were al-
lowed to recover for 10 d before wounding. All mice were anesthetized
with halothane, and the dorsum was shaved and cleaned with 70% al-
cohol. Three-millimeter full-thickness cutaneous punch-biopsy wounds
were made maintaining the underlying fascia. The wounded tissue was
collected at 0 and 7 d post-injury, bisected, and either fixed in 10%
formalin at room temperature for 24 h, or in acid alcohol (96% ethanol/
1% acetic acid) at 4°C for paraffin embedding, or snap-frozen in OCT
(Thermo Lifesciences) and stored at −80°C for cryo-sectioning.
Time-lapse microscopy
K14CreErT2/FAKflox/flox keratinocytes were harvested as described and
plated onto collagen-I-coated six-well tissue culture dishes (Becton Dick-
inson). Following 4-OHT or vehicle alone treatment, cells were moni-
tored using time-lapse video microscopy with images captured from each
well every 20 min over a 10-h period. Quantification of cell motility was
achieved by analysis of captured images using cell tracking software (Ke-
netic Imaging Ltd).
Confocal immunofluorescence microscopy
K14CreErT2/FAKflox/flox keratinocytes were grown on glass coverslips,
fixed at room temperature for 10 min with 3.7% formaldehyde/PBS, and
permealized with 0.5% Triton X-100 in PBS and incubated with anti-FAK
mAb (Transduction Laboratories). Antibody detection was via fluores-
cein isothiocynate-conjugated goat anti-mouse IgG (Jackson), for 45 min
at room temperature. Fluorescence was visualized using a Bio-Rad MRC
600 confocal microscope.
FACS analysis
K14CreERT2/FAKflox/flox keratinocytes were either treated with 4-OHT
or vehicle alone, washed 1× in PBS, and fixed in 70% ethanol for 3 h at
4°C. Fixed cells were pelleted at 1000 rpm for 5 min, washed 1× in PBS,
and resuspended in propidium iodide solution (1 mg/mL). Labeled cell
populations were analyzed by fluorescence activated cell sorting (FACS)
analysis using a Becton Dickinson Cellquest FACScan.
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